Bioepis Details Don't Support the Valuation
We are following up on our previous post on the proposed listing of Samsung BioLogics US$9 Billion Valuation Is Rarefied Air in response to...
286 Views
SillaJen's December IPO: Valuation, Growth Expectation and IPO Timing
SillaJen Biotherapeutics (established in 2006) is indeed a rare breed in Korean pharmaceutical world. It is not a generic drug maker. It is not a...
3.4k Views
Study Highlights Hurdles to U.S. Uptake of Inflectra
A new study (abstract attached) presented at the European Union League Against Rheumatism (EULAR) Conference highlights one of the main hurdles to...
187 Views
U.S. Remsima Expectations Too Optimistic
USFDA approved Celltrion’s Remsima, a biosimilar for JNJ’s Remicade, for use in treating rheumatoid arthritis, ulcerative colitis, Crohn’s, and...
213 Views
The Risks of High Expectations for Biosimilars
Celltrion trades at a premium valuation (35x 2016 estimated earnings) based on high expectations for its biosimilar (copycats of biotech) products....
267 Views